Cargando…
Effectiveness of Convalescent Plasma Therapy in COVID-19 Patients with Hematological Malignancies: A Systematic Review
Background: Immunocompromised patients, including those with hematological malignancies, are at a high risk of developing severe coronavirus disease 2019 (COVID-19) complications. Currently, there is a limited number of systematic reviews into the efficacy of convalescent plasma therapy (CPT) use in...
Autores principales: | Shibeeb, Sapha, Ajaj, Ilham, Al-Jighefee, Hadeel, Abdallah, Atiyeh M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778836/ https://www.ncbi.nlm.nih.gov/pubmed/36547236 http://dx.doi.org/10.3390/hematolrep14040052 |
Ejemplares similares
-
Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies
por: Jeyaraman, Preethi, et al.
Publicado: (2021) -
ABO blood group association and COVID-19. COVID-19 susceptibility and severity: a review
por: Shibeeb, Sapha, et al.
Publicado: (2022) -
Thrombotic and Hypercoagulability Complications of COVID-19: An Update
por: Shibeeb, Sapha, et al.
Publicado: (2021) -
Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19
por: Biernat, Monika Maria, et al.
Publicado: (2021) -
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
por: Thompson, Michael A., et al.
Publicado: (2021)